SOLARA · Solara Active Pharma Sciences Ltd · Biotechnology & Drugs
SOLARA · Solara Active Pharma Sciences Ltd · Biotechnology & Drugs
As of 06 Nov close
52-week range
18.2% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹382 Cr
Revenue YoY
PAT YoY
+55.0%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
4
P/S (TTM)
2.5
Sector P/E
36.3
Dividend yield
0.0%
Source: Yahoo Finance, as of 29 Oct 2026
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| SOLARA (this stock) | 85 | 4 | -0.1% | -0.1% | 0.55 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
falling 1q
FII
rising 1q
MF
0.95% (-0.21pp)
falling 1q
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| date | canonicalSymbol | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| 2026-10-16 | SOLARA | 260455 | 1 | WEAK | BULK |
| 2026-08-20 | SOLARA | 283420 | 1 | WEAK | BULK |
| 2026-07-10 | SOLARA | 0 | 0 | STRONG | BULK |
News timeline
- lowgurufocus.com· 18 Oct 2026, 06:18 amQ2 2027 Solara Active Pharma Sciences Ltd Earnings Call Transcript
- lowthehindubusinessline.com· 16 Oct 2026, 08:24 amQ2 Results 16th Oct Live: DLF, LTM, Oberoi Realty, Punjab National Bank, Himadri Speciality Chemical, Federal Bank Q2 results Today, Nestle, Jio, Wipro, Tech Mahindra, HDFC Life, HDFC AMC, Persistent
- loweconomictimes.indiatimes.com· 16 Oct 2026, 06:47 amStocks in news: RIL, Wipro, Jio Financial, Tata Communications, YES Bank, PNB
- lowbusiness-standard.com· 13 Oct 2026, 08:40 pmNuSynth Technologies raises ₹36.5 crore in seed funding led by two VCs
Concalls & investor presentations
AI-generatedKey takeaway: Solara Active Pharma Sciences Limited reported strong Q2 FY27 results, with revenue growing 33% year-on-year to INR418 crores, driven by a 37% increase in its base business to INR327 crores. EBITDA more than doubled to INR77 crores (up 118%), and PAT improved significantly to INR28.5 crores, compared to a loss of INR10 crores in the same period last year. The company noted that the West Asia crisis continued to impact raw material availability and pricing, but it managed to maintain profitability through improved pricing and operational efficiency. The Ibuprofen business showed improvement, with revenue up 21% year-on-year and EBITDA loss narrowing significantly. Management highlighted strategic reviews of the Ibuprofen business, aiming to finalize decisions within 12 weeks. The company also mentioned filing five DMFs in FY27, with two already completed, and noted a CRISIL ESG rating upgrade to 'strong'. Net debt was reduced to INR500 crores from INR614 crores, improving the Net Debt to EBITDA ratio to 1.8x. The company emphasized continued focus on cost control, margin expansion, and working capital discipline.
The document highlights strong revenue and profit growth, improved EBITDA, and positive strategic developments such as the CRISIL ESG rating upgrade and reduced net debt.
Sourced from an exchange-filed transcript, dated 23 Oct 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: During the earnings conference call for Q1 FY27, management reported that Solara Active Pharma Sciences achieved revenues of INR 384 crores, reflecting a 20% year-on-year increase. EBITDA rose to INR 63.5 crores, up 10% year-on-year, while PAT reached INR 16.3 crores, marking a 55% increase year-on-year. Management highlighted strong performance in the base business, with revenues of INR 307 crores, a 24% year-on-year growth. Despite challenges in the Ibuprofen segment, which faced profitability issues, management noted a marginal sequential improvement. The company emphasized its commitment to operational efficiency and sustainable profitability growth, while also addressing the impact of geopolitical developments on raw material costs. Management expressed confidence in the long-term growth potential of the base business and thanked shareholders for their support.
Management emphasized strong financial performance and growth in the base business.
Sourced from an exchange-filed transcript, dated 29 Jul 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Management reported that Q4 FY26 was a strong quarter for Solara Active Pharma Sciences Limited, achieving the highest revenue, gross margins, and EBITDA in the last eight quarters. The company experienced a 12% quarter-on-quarter revenue growth, reaching INR 392 crores, and a significant 65% increase in EBITDA, amounting to INR 61 crores. The base business was highlighted as the primary driver of this performance, operating at a 26% EBITDA margin. However, management acknowledged ongoing challenges in the ibuprofen segment, which recorded a negative EBITDA, and stated that strategic options for this business are being evaluated. The company also reported a 21% reduction in debt during FY26 and expressed confidence in maintaining operational efficiency and margin expansion moving forward. Management emphasized a focus on sustainable growth and improving customer relationships.
Management highlighted strong financial performance and growth in the base business.
Sourced from an exchange-filed transcript, dated 21 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The earnings conference call for Solara Active Pharma Sciences Limited, held on February 6, 2026, addressed the company's performance for the third quarter and nine months ended December 31, 2025. Management reported significant challenges in the ibuprofen business, which has been impacted by excess capacity and pricing pressures, leading to a low capacity utilization of approximately 3,000 tons out of 12,000 tons. Despite these struggles, the non-ibuprofen segment showed strong performance with gross margins of 56% and EBITDA of 25%. Management indicated plans to seek external advice regarding the future of the ibuprofen business while focusing on growth in the non-ibuprofen sector. The company reported a 10% quarter-on-quarter revenue growth, totaling INR 346 crores, although gross margins decreased to 47%. Management emphasized a commitment to operational efficiency and a healthier balance sheet, having reduced debt by 19%.
Management highlighted both challenges in the ibuprofen business and positive growth in the non-ibuprofen segment.
Sourced from an exchange-filed transcript, dated 10 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedSolara Active Pharma Sciences Limited's FY2025-26 annual report highlights the company's commitment to corporate governance, sustainability, and strategic growth. The report emphasizes adherence to high standards of governance, including transparency, accountability, and ethical conduct. It outlines the company's focus on maintaining compliance with regulatory requirements and industry best practices. Additionally, the report details the company's sustainability initiatives, including investments in renewable energy and efforts to reduce greenhouse gas emissions. The company also discusses its robust risk management framework and the performance evaluation of its Board and committees.
- Commitment to high standards of corporate governance with a focus on transparency, accountability, and ethical conduct.
- Sustainability initiatives including investments in renewable energy and reduction of greenhouse gas emissions.
- Robust risk management framework and regular evaluation of Board performance and committees.
Key takeaway: Solara Active Pharma Sciences Limited is committed to maintaining high standards of corporate governance and sustainability, supported by a robust risk management framework and regular evaluation of its Board and committees.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Default / Covenant Breach (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Default / Covenant Breach
1 occurrenceEarlier (1-3 years ago)
The company has statutory dues pending with various authorities including GST, Excise, Customs, and Income Tax for periods ranging from FY 2011-12 to FY 2022-23, with amounts involved and unpaid specified in crores.
Routine disclosures
Contingent Liability
2 occurrencesRecent (last 12 months)
The company has pending litigations related to indirect and direct taxes, including assessment orders from the assessing officer for the assessment year 2018-19 where depreciation on goodwill and product portfolio was disallowed.
Earlier (1-3 years ago)
The company has pending litigations related to indirect and direct taxes, including assessment orders from the assessing officer for the year 2018-19 where depreciation on goodwill and product portfolio was disallowed.
Related-Party Transaction
3 occurrencesRecent (last 12 months)
Solara derived INR328 crores of revenue in FY '26 from Strides, a related party, which accounted for a quarter of FY '26 revenue. Receivables from Strides increased from INR63 crores to INR160 crores.
Solara Active Pharma Sciences Limited approved material related party transactions with Strides Pharma Science Limited up to 480 crores.
Earlier (1-3 years ago)
Shareholders approved material related party transactions with M/s. Strides Pharma Science Limited up to a maximum of 400 crores.
Statutory dues in dispute
1 occurrenceRecent (last 12 months)
The company has statutory dues under the Central Excise Act, 1944 that are disputed and pending resolution, with an amount involved of ` in Crore and an amount unpaid of ` in Crore.
Management & Board Governance
2 occurrencesRecent (last 12 months)
Poorvank Purohit, Managing Director and Chief Executive Officer, resigned effective February 21, 2025.
Earlier (1-3 years ago)
Poorvank Purohit resigned as Managing Director and CEO effective February 21, 2025. Sandeep Rao was appointed as Managing Director and CEO effective February 21, 2025.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
20.59% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).